FindTrial
Sign In

An Ayurvedic Clinical study to evaluate the efficacy of different forms and doses of CURCUMIN for Rheumatoid Arthritis patients.

A Randomized, Double Blind, Placebo Controlled, Four Arm, Parallel Group Study To Evaluate The Comparative Efficacy Of Different Forms And Doses Of Curcumin With That Of A Placebo In Active Rheumatoid Arthritis Patients.

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011617
Enrollment
48
Registered
2018-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- RHEUMATOID ARTHRITIS PATIENTS

Interventions

Intervention1: Curcumin 500 mg, Curcumin 250 mg, white curcumin: oral route of administration, One capsule per day Control Intervention1: Active :CURCUMIN Comparator:Plcebo: All enrolled 48 subjects w

Sponsors

Plant Lipids P Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: i.Patients with active RA for at least one (1) year, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis. ii.Receiving treatment on an outpatient basis. iii.Active disease at the time of screening.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
To evaluate the comparative efficacy of curcumin (low & high dose), white curcumin with that of a placeboTimepoint: Screening â?? (Day - 7) Baseline visit â?? (Day 0) Visit 2 (Day 30) Visit 3 (Day 60) Visit 4 (Day 90)—

Secondary

MeasureTime frame
a. To assess the safety & tolerability of active products b. To assess changes in various biomarkers during the study period among all the study group subjects. Timepoint: Day 0 Day 30 Day 60 Day 90—

Countries

India

Contacts

Public ContactJeevan

Nil

prasannamathad@gmail.com08389231551

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026